Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Daratumumab-based maintenance regimens show favourable responses in transplant...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Daratumumab-based maintenance regimens show favourable responses in transplant-eligible NDMM ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )

Approaches to risk stratification in high risk myeloma

Dr Irene Ghobrial - Dana-Farber Cancer Institute, Boston, USA

Approaches to risk stratification in high risk myeloma ( Dr Irene Ghobrial - Dana-Farber Cancer Institute, Boston, USA )

Tailored to fit: New approaches in transplant-ineligible NDMM

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Tailored to fit: New approaches in transplant-ineligible NDMM ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Advancements in minimal residual disease detection in myeloma

Dory Abelman, PhD Candidate - University of Toronto, Ontario, Canada

Advancements in minimal residual disease detection in myeloma ( Dory Abelman, PhD Candidate - University of Toronto, Ontario, Canada )

Novel biomarkers in myeloma: CTCs and cfDNA

Dr Bruno Paiva - Clinica Universidad de Navarra, Pamplona, Spain

Novel biomarkers in myeloma: CTCs and cfDNA ( Dr Bruno Paiva - Clinica Universidad de Navarra, Pamplona, Spain )

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new...

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Use of bispecifics and CAR T cells in South America

Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Use of bispecifics and CAR T cells in South America ( Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

More from ecancer